Last 457.50 GBp
Change Today +10.50 / 2.35%
Volume 7.1K
IVO On Other Exchanges
Symbol
Exchange
London
Berlin
As of 11:35 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Julian Mathew Smith

Former Chief Financial Officer, Chief Operations Officer, Executive Director and Member of Investment Committee, Imperial Innovations Group plc
AgeTotal Calculated CompensationThis person is connected to 7 board members in 1 different organizations across 4 different industries.

See Board Relationships
49--
As of Fiscal Year 2014

Background*

Mr. Julian Smith has been the Chief Financial Officer of Abzena plc since September 09, 2013. Mr. Smith has been the Chief Operating Officer of Antitope Ltd. since September 2013. Mr. Smith served as the Chief Operations Officer and Chief Financial Officer at Cortexica Vision Systems Limited since January 2006. Mr. Smith served as the Chief Financial and Operating Officer of Imperial Innovations Group plc from January 3, 2006 to April 2013. Mr. Smith spent six years ...

Read Full Background

Corporate Headquarters*

52 Princes Gate
London, Greater London SW7 2PG

United Kingdom

Phone: 44 20 7581 4949
Fax: 44 20 7594 6584

Board Members Memberships*

Former Chief Financial Officer
2006-2013
Former Chief Financial Officer, Chief Operations Officer, Executive Director and Member of Investment Committee
2013-Present
Chief Financial Officer, Company Secretary and Executive Director

Education*

MA
University of Oxford

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IVO:LN 457.50 GBp +10.50

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Judith Greciet Ph.D., PharmacyChief Executive Officer, Director and Member of Corporate Development Committee
Onxeo SA
€276.9K
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Peter William Grant Chief Executive Officer and Executive Director
Skyepharma PLC
567.0K GBP
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Michael Scott Maguire MBAChief Executive Officer, President and Director
Xenetic Biosciences, Inc.
$877.0K
Compensation as of Fiscal Year 2012.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPERIAL INNOVATIONS GROUP P, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.